Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ligand Pharm (NQ: LGND ) 82.70 -2.09 (-2.46%) Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Ligand Pharm < Previous 1 2 3 Next > Lifecore Biomedical Announces Cooperation Agreement with 22NW July 01, 2024 Provides for the Addition of 22NW Nominees Jason Aryeh and Matthew Korenberg, as Well as Humberto Antunes and Paul Johnson, to the Board From Lifecore Biomedical, Inc. Via GlobeNewswire Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years June 27, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults June 18, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand to Participate in Upcoming Investor Conferences May 23, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Reports First Quarter 2024 Financial Results May 07, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement May 07, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand to Report First Quarter 2024 Financial Results on May 7, 2024 April 23, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference April 08, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™ April 03, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference March 05, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 04, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Pharmaceuticals Inc. (NASDAQ: LGND) Making Surprising Moves in Tuesday Session February 27, 2024 Via Investor Brand Network Ligand Reports Fourth Quarter and Full Year 2023 Financial Results February 27, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa® February 22, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires February 16, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 February 13, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 01, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum January 05, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance December 12, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City December 06, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications December 01, 2023 From Palvella Therapeutics Via GlobeNewswire Ligand Reports Third Quarter 2023 Financial Results November 08, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Acquires Royalty on Sanofi’s TZIELD® for $20 Million November 01, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand To Report Third Quarter 2023 Financial Results On November 8 October 25, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026 October 18, 2023 From Ovid Therapeutics Inc. Via GlobeNewswire Ligand Acquires Assets of Novan, Inc. for $12.2 Million September 27, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Appoints Martine Zimmermann to its Board of Directors September 26, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma September 22, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand’s Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control September 21, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio September 18, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.